Cargando…
A PDGFRB- and CD40-targeting bispecific AffiMab induces stroma-targeted immune cell activation
CD40 agonism by systemic administration of CD40 monoclonal antibodies has been explored in clinical trials for immunotherapy of cancer, uncovering enormous potential, but also dosing challenges in terms of systemic toxicity. CD40-dependent activation of antigen presenting cells is dependent on cross...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332328/ https://www.ncbi.nlm.nih.gov/pubmed/37332119 http://dx.doi.org/10.1080/19420862.2023.2223750 |